Just six months after paying $2.5 billion to establish a commercial rare-disease platform around ALS therapy Radicava (edaravone), Shionogi & Co. Ltd. is doubling down with a planned $2 billion ...

Partners Abbvie Inc. and Genmab A/S may be able to file earlier than expected to bring the T-cell engaging bispecific antibody Epkinly (epcoritamab) into a broader diffuse large B-cell lymphoma (DLBCL ...

One of the players in what was shaping up as a three-way battle took a hit when Arrivent Biopharma Inc. rolled out results ...

Becton, Dickinson and Co. (BD) plans to invest $19 billion in the U.S. over several years as part of a deal with the U.S.

Rougetx has raised $58 million in series A funding to move disease-modifying small molecules into the clinic for the treatment of vascular conditions that are driven by pericyte dysfunction. The first ...

August 2026 brought 93 clinical trial updates tracked by BioWorld, with late-stage programs accounting for the largest share ...

The U.S. FDA has cleared Hanchorbio Inc.’s IND application for HCB-303, the company’s second trispecific immunotherapy to ...

Vaxcyte Inc. did even better than expected against competitors in the Opus-1 pivotal phase III trial that tested the safety, ...

Alector Inc. is getting $100 million up front, with the potential of up to $1.17 billion in milestones, in a deal with Roche ...

Myotonic dystrophy type 2 (DM2) is a neuromuscular disease caused by the expansion of CCTG repeats affecting intron 1 in the CNBP gene, which leads to toxic intronic RNA accumulation and sequestration ...

The Nobel Assembly at Karolinska Institutet announced today that it has awarded the 2026 Nobel Prize in Physiology or Medicine to three scientists “for their discoveries concerning light-gated ion ...

CSL Ltd. is making one of its biggest strategic bets yet on nephrology, agreeing to pay Alentis Therapeutics SA $355 million up front and up to $1.2 billion in milestones to co-develop lixudebart, a ...